Coronavirus: Italy claims world’s first Covid-19 vaccine developed

Vaccine has neutralized the virus in human cells

Coronavirus: Italy claims world's first Covid-19 vaccine developed

Coronavirus: Italy claims world’s first Covid-19 vaccine developed

Italian researchers have claimed that they have successfully developed a vaccine to contain coronavirus (Covid-19) which is likely to work on humans, a report said.

According to the tests carried out at Rome’s infectious-disease Spallanzani Hospital, an Italian coronavirus vaccine has antibodies generated in mice that work on human cells, the report stated.

The breakthrough development made by the researchers at Lazzaro Spallanzani National Institute for Infectious Diseases, said that a coronavirus candidate vaccine has neutralized the virus in human cells for the first time.

As far as we know we are the first in the world so far to have demonstrated neutralization of the coronavirus by a vaccine. We expect this to happen in humans too, Aurisicchio added.

So far, the immunity generated by most of our five vaccine candidates has an effect on the virus. 

The team said they are expected to test its vaccine on humans after summer.

For this to succeed, they need the support not only from their government but as well as international institutions and partners who might want to extend their hand to help speed up the process.

The total number of coronavirus (Covid-19) infections, fatalities and recoveries since the pandemic began has risen to 213,013 in Italy.

World Health Organization (WHO): Vaccine Update

According to World Health Organization (WHO) recent update, eight COVID-19 vaccine candidates are right now in the human trial phase.

Four of these are from China, three from the USA, and one from the UK. Of eight, seven are in phase 1 and 2 of trials.

Phase 1 of human trials is usually safety trials which are done on about 100 or fewer people while phase 2 involves 100s of people at once to test the safety and efficacy of the vaccine. For the combined phase I and II, these potential COVID-19 vaccines will be tested on 1000s of patients in various study groups.